Estrella Immunopharma - רווח למניה בשנים עשר החודשים האחרונים ESLA

Estrella Immunopharma (ESLA) is recognized by hematologists for its CAR-T methods that reduce toxicity. High R&D expenditures and stringent FDA oversight create significant barriers to entry. Revenues are based on the commercialization of cell therapies for lymphomas. The rolling trailing twelve-month earnings per share helps avoid overpayment, while the value of -0.25 captures the metric level.
פילוחים אנליטיים ודוחות נתונים של חברת Estrella Immunopharma Corp (ESLA)

Investors utilize this metric as the primary criterion for assessing the real yield of each share. The metric is calculated by dividing the total annual net income by the total number of securities. Analyzing this chart of net income per share over the last 12 months reveals historical valuation extremes. For Estrella Immunopharma (ESLA), the trend of this value depends directly on the efficiency of external R&D contractors. A high reliance on outsourced clinical trials makes earnings sensitive to the operational schedules of third-party vendors.